Literature DB >> 6436463

Acute intravenous infusion of disodium dihydrogen (1-hydroxyethylidene)diphosphonate: mechanism of toxicity.

M D Francis, C L Slough.   

Abstract

The acute intravenous toxicity of disodium dihydrogen (1-hydroxyethylidene)diphosphonate (etidronate disodium; I) and the mechanism of this toxic response have been investigated in 40 beagle dogs. The intravenous toxicity of I is dependent on the total dose administered and the length of the infusion interval. The toxicity of I is directly related to the ability of the drug to bind or complex with the circulating calcium in the blood. Maximum depressions in ionized calcium coincide in time with peak blood levels of I, and at lethal doses electrocardiographic changes indicative of hypocalcemia are observed. For a 2-min infusion of 2 mg of I/kg, no effect is observed on ionized calcium levels, and the electrocardiogram remains normal. At doses of 16 and 32 mg/kg, coincident with an immediate fall in ionized calcium levels, there is a transient rise in total calcium and a fall in phosphorus levels. The ionized calcium level rises, and total calcium level falls and stabilizes at baseline levels within 30 min after the infusion. However, the phosphorus level rises and exceeds the baseline value, reaching 3-4 times normal by 72 h after the infusion. With proven lethal doses of I (60 mg/kg infused over 2 min) and the simultaneous infusion of an ionized calcium salt such as calcium gluconate (20 mg of Ca2+/kg), electrocardiograms remain normal and death is prevented. Thus, an effective antidote in the event of an overdose or too rapid an infusion of I can be employed to prevent acute toxic effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436463     DOI: 10.1002/jps.2600730818

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium.

Authors:  N Varma; G N Kerrigan
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

4.  Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Authors:  M Pecherstorfer; E U Steinhauer; R Rizzoli; M Wetterwald; B Bergström
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

5.  Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease.

Authors:  Nina V Lyubimova; Nikolay E Kushlinsky; Michail R Lichinitser; Karl Schlosser
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.